Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01160445 | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00747305 | Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery | terminated | Phase 1 | 17 | Harry DrabkinOTHER | 1 | Oct 22, 2015 | clinicaltrials |
| NCT01342627 | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma(SERCC) | terminated | Phase 2 | 4 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01100242 | Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 17 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00601926 | Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 2 | 5 | Paul MonkOTHER | 1 | Jun 15, 2015 | clinicaltrials |
| NCT00589550 | PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 | 1 | Thomas OlenckiOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00491621 | Evaluation of Diagnostic Value of Molecular Markers in Renal Cancer(CMM) | terminated | N/A | 74 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01507740 | Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients | terminated | — | 60 | Medical University InnsbruckOTHER | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00930345 | Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma(PREINSUT) | terminated | Phase 4 | 33 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 1, 2015 | clinicaltrials |
| NCT01547676 | Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer | terminated | N/A | 28 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2015 | clinicaltrials |
| NCT01720693 | Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy | terminated | Phase 2 | 3 | University Health Network, TorontoOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00352859 | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | terminated | Phase 4 | 2 | BayerINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00622479 | Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. | terminated | Phase 1 | 12 | BayerINDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01486550 | Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy(VONE) | terminated | Phase 4 | 14 | Regional Hospital HolstebroOTHER | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00001703 | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT01793636 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer(ZEBRA) | terminated | Phase 2 | 49 | Queen Mary University of LondonOTHER | 1 | Jun 24, 2014 | clinicaltrials |
| NCT01068470 | Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy(LAK) | terminated | — | 11 | Loma Linda UniversityOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00523640 | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 30 | University of ChicagoOTHER | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00942058 | Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer(CA9CRM) | terminated | — | 16 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jan 29, 2014 | clinicaltrials |
| NCT01677390 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma | terminated | Phase 1 | 4 | Seagen Inc.INDUSTRY | 1 | Jan 28, 2014 | clinicaltrials |
| NCT00176501 | Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer | terminated | Phase 2 | 3 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT01063998 | A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma | terminated | — | 23 | Jason HafronOTHER | 1 | Nov 8, 2013 | clinicaltrials |
| NCT00110344 | Research Study for Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 1 | BayerINDUSTRY | 1 | Oct 11, 2013 | clinicaltrials |
| NCT00289146 | Comparison of Immune Response Following Surgical Management of Renal Tumors | terminated | — | 50 | Emory UniversityOTHER | 1 | Sep 24, 2013 | clinicaltrials |
| NCT00203866 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 40 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | Accelerated Community Oncology Research NetworkOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00896467 | Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy | terminated | — | 200 | Centre Oscar LambretOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01073644 | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients | terminated | — | 3 | PfizerINDUSTRY | 1 | Jul 4, 2013 | clinicaltrials |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT01466504 | Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | terminated | — | 4 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 15, 2013 | clinicaltrials |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00816686 | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer | terminated | Phase 1 | 7 | Astellas Pharma IncINDUSTRY | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00009919 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00091611 | Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer | terminated | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 26, 2012 | clinicaltrials |
| NCT00492440 | Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer | terminated | Phase 1 | 9 | Cytheris SAINDUSTRY | 1 | Oct 18, 2012 | clinicaltrials |
| NCT00126178 | Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer | terminated | Phase 3 | 600 | Agenus Inc.INDUSTRY | 2 | Sep 7, 2012 | clinicaltrials |
| NCT01197820 | Hepatic and Renal Thermography Using Magnetic Resonance Imaging(THeR-IRM) | terminated | N/A | 15 | University Hospital, BordeauxOTHER | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00243009 | Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery | terminated | Phase 2 | 1 | OHSU Knight Cancer InstituteOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00311467 | Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma | terminated | Phase 3 | 172 | Central European Cooperative Oncology GroupOTHER | 1 | May 16, 2012 | clinicaltrials |
| NCT00100685 | Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | terminated | Phase 2 | 48 | AbbottINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
| NCT01033981 | Cost Effectiveness Of Sunitinib In Central America And Caribbean | terminated | — | 4 | PfizerINDUSTRY | 1 | Apr 19, 2012 | clinicaltrials |
| NCT00485563 | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | EndocyteINDUSTRY | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00561912 | Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 26, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Oct 28, 2015source: clinicaltrials